Cohance Lifesciences Limited (BOM:543064)

Market Cap	207.56B
Revenue (ttm)	12.11B
Net Income (ttm)	1.77B
Shares Out	n/a
EPS (ttm)	6.88
PE Ratio	117.27
Forward PE	41.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,679
Average Volume	162,454
Open	543.05
Previous Close	549.10
Day's Range	533.85 - 548.20
52-Week Range	533.85 - 1,337.85
Beta	n/a
RSI	17.92
Earnings Date	Nov 12, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.